Selected article for: "clinical status and moderate clinical status"
Author: Aleissa, Muneerah M.; Silverman, Emily A.; Paredes Acosta, Luisa M.; Nutt, Cameron T.; Richterman, Aaron; Marty, Francisco M.
Title: New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
  • Cord-id: 0ban6dpu
  • Document date: 2020_12_16
    • ID: 0ban6dpu
    Snippet: Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families, including Coronaviridae. Preclinical data in animal models of coronavirus diseases, including COVID-19, have demonstrated that early treatment with remdesivir leads to improved survival, decreased lung injury, and decreased levels o
    Document: Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families, including Coronaviridae. Preclinical data in animal models of coronavirus diseases, including COVID-19, have demonstrated that early treatment with remdesivir leads to improved survival, decreased lung injury, and decreased levels of viral RNA. Recent clinical data have demonstrated the clinical activity of remdesivir in terms of faster time to recovery in patients with severe COVID-19 and higher odds of improved clinical status in patients with moderate COVID-19. Here, clinical trials published to date are presented and appraised. Remdesivir’s potential benefits and its favorable adverse-event profile make it an option for the treatment of COVID-19. This article examines the available literature describing remdesivir’s pharmacology, pharmacokinetics, and preclinical and clinical data.

    Search related documents:
    Co phrase search for related documents
    • active metabolite and acute respiratory distress syndrome: 1, 2, 3
    • active metabolite and acute respiratory failure: 1
    • acute kidney injury and additional intervention: 1
    • acute kidney injury and liver aminotransferase: 1, 2
    • acute respiratory distress syndrome and adaptive trial: 1, 2, 3
    • acute respiratory distress syndrome and additional intervention: 1, 2
    • acute respiratory distress syndrome and administration proportion: 1
    • acute respiratory distress syndrome and liver aminotransferase: 1, 2, 3, 4, 5
    • acute respiratory failure and adaptive trial: 1
    • acute respiratory failure and additional intervention: 1
    • acute respiratory failure and administration follow: 1
    • acute respiratory failure and live discharge: 1, 2
    • adaptive trial and live discharge: 1